Abstract
Objective To evaluate the impact of isoniazid on incident tuberculosis in household contacts of MDR tuberculosis cases.
Design Systematic review and individual-participant meta-analysis.
Data sources MEDLINE, Web of Science, BIOSIS, and Embase without language restrictions for case-contact cohort studies of tuberculosis contacts.
Eligibility criteria and data analysis Household contact tracing studies that investigated the development of tuberculosis in persons closely exposed to individuals with tuberculosis and followed for incident disease. Both retrospective and prospective cohort studies were included. Participants were included if they were exposed to someone with multidrug-resistant tuberculosis and were given either 6 months of isoniazid TPT or no TPT. Two reviewers independently assessed quality using a modified quality assessment of tool. We derived adjusted hazard ratios (aHRs) for incident tuberculosis using mixed-effects, multivariable Cox regression models with study-level random effects. The effectiveness of isoniazid TPT against incident tuberculosis was estimated through propensity score matching. We stratified our results by contact age, HIV, and Mycobacterium tuberculosis infection status.
Main outcome measures Our primary outcome was incident tuberculosis in contacts exposed to tuberculosis (defined as a diagnosis >90 days after baseline). We derived adjusted hazard ratios (aHRs) for incident tuberculosis using mixed-effects, multivariable Cox regression models with study-level random effects.
Results We included participant-level data from 4,945 contacts exposed to multidrug-resistant tuberculosis from eight countries. The effectiveness of 6 months of isoniazid TPT against tuberculosis in contacts of multidrug-resistant tuberculosis was 70% (aHR, 0.30; 95% CI, 0.16–0.56) and did not appreciably change with adjustment for additional potential confounders. Effectiveness was higher among contacts <18 years of age (aHR, 0.39; 95% CI, 0.18–0.87) compared to adult contacts (aHR, 0.44; 95% CI, 0.14–1.41). Effectiveness was 93% (aHR, 0.07; 95% CI, 0.02–0.52) in the first year of follow-up; effectiveness dropped to 80% (aHR, 0.20; 95% CI, 0.05–0.89) in the second year and was non-significant after two years (26% effectiveness; aHR, 0.74; 95% CI, 0.34–1.59).
Conclusions Among almost 5,000 contacts of multidrug-resistant tuberculosis cases, isoniazid IPT was 70% effective against incident tuberculosis. Protection waned after 2 years of follow-up. These results have important implications for the clinical management of individuals exposed to multidrug-resistant tuberculosis and future clinical trials.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Boston University waived ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used for this analysis can be made available upon reasonable request to the corresponding author once all relevant substudies from the consortium have been completed.
